Episode 1: Clinical and Economic Burden of Influenza and its Associated Complications

Activity Details
  • Credit Type: Other
  • Credit Amount: 0.75
  • Cost: Free
  • Release: Oct 18, 2017
  • Expires: Oct 18, 2018
  • Estimated Time to Complete:
    45 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)


Thomas M.  File Jr Thomas M. File Jr, MD, MSc, MACP, FIDSA, FCCP
Chair, Infectious Disease
Summa Health System
Akron, Ohio
Professor, Internal Medicine
Master Teacher and Chair, Infectious Disease
Northeast Ohio Medical University
Rootstown, Ohio

Needs Statement

Seasonal influenza remains a serious and life-threatening disease, attributing to 34,000-49,000 deaths annually in the United States. Additionally, influenza can cause serious complications and hospitalization in elderly patients or those with chronic health conditions such as asthma, diabetes, heart disease, and immunosuppression.

Primary care providers (PCPs) play an integral role in the care of patients during well and sick visits. 

PCPs must be knowledgeable about vaccines, be able to identify patients at high risk of severe disease and complications from influenza, and incorporate systems into clinical practice to ensure that there are no missed opportunities to offer and administer vaccines (e.g., timely reminders to encourage vaccination).

Target Audience

Primary care providers including internists, family physicians, nurse practitioners, and physician assistants who play an integral role in the care of patients during well and sick visits.


Upon completion of this educational activity, participants will be able to:

  • Describe the clinical and economic burden associated with seasonal influenza
  • Recognize patient types that are predisposed to serious complications, hospitalization, or death associated with influenza
  • Differentiate among the current FDA-approved influenza vaccines
  • Recognize how patient factors and preferences can influence optimal vaccine selection
  • Identify communication techniques that can be utilized to overcome vaccine avoidance and increase influenza vaccination rates
  • Recognize institutional policies that can help promote vaccination in their practice setting


UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

Thomas M. File, Jr., MD MSc, MACP, FIDSA, FCCP, has relevant financial relationships with commercial interests as follows:
Allergan, Bayer, BioMerieux, The Medicines Company, Merck, Paratek, and Pfizer - Consultant - Consulting Fee
Nabriva - Research Grant - Grant to Institution

No planner or content reviewer have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


This activity is jointly provided by the University of Kentucky and Vemco MedEd.

Supported by an unrestricted educational grant from Sanofi Pasteur.

CE Content Concerns


Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504


  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.